uniQure (NASDAQ:QURE) Shares Pass Above 200-Day Moving Average – Here’s Why

uniQure (NASDAQ:QURE)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $9.38 and traded as high as $14.24. uniQure shares last traded at $14.18, with a volume of 595,499 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price target on shares of uniQure in a research note on Tuesday, January 21st. Cantor Fitzgerald boosted their price target on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Guggenheim restated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Wells Fargo & Company upgraded shares of uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

uniQure Stock Up 7.0 %

The business’s 50-day simple moving average is $15.54 and its 200 day simple moving average is $9.44. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm has a market cap of $691.13 million, a PE ratio of -2.86 and a beta of 0.38.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. lifted its stake in uniQure by 49.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after acquiring an additional 89,400 shares during the period. Ballentine Partners LLC acquired a new position in shares of uniQure in the 3rd quarter valued at $116,000. abrdn plc increased its holdings in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after acquiring an additional 1,528,581 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares in the last quarter. Finally, Atria Investments Inc purchased a new stake in shares of uniQure during the third quarter worth $53,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.